DiaSorin said on Friday that its third quarter revenues fell 17 percent year over year as COVID-19 testing revenues continued an expected decline and losses in non-COVID molecular diagnostics and licensing businesses further offset gains in the company's immunodiagnostics business.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2023.

Abbott announced on Thursday that its molecular test for human papillomavirus has received regulatory approval from the US Food and Drug Administration.

Guardant Health and Flatiron Health on Tuesday said they inked a deal that will integrate Guardant's genomic profiling tests into Flatiron's cloud-based electronic medical record management platform.

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the third quarter ended October 1, 2023.

On 27 October, Ministry of Finance of the People’s Republic of China and National Health Commission of the People’s Republic of China issued a notice.

On October 25, 2023, during the 2023 Boehringer Ingelheim China R&D Day event, Burning Rock and Boehringer Ingelheim officially signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics.

GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today reported financial results for the third quarter ended September 30, 2023.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 1, 2023.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter and first nine months of 2023.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Werfen announced recently that its subsidiary Inova Diagnostics has secured US Food and Drug Administration 510(k) clearance for a blood-based immunoassay reagent used to aid the diagnosis of connective tissue diseases.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023.

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023.